echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Haisco submits a marketing application for the fourth indication of cyclopofol injection

    Haisco submits a marketing application for the fourth indication of cyclopofol injection

    • Last Update: 2021-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 30, Haisco issued an announcement stating that its innovative drug cyclopofol injection for the indication of "general anesthesia induction and maintenance" has been recently accepted by the Drug Evaluation Center of the China National Medical Products Administration


    Cycloprofen injection (R&D code HSK3486) is an intravenous anesthetic with independent intellectual property rights developed by the company for many years, and it is also the company's first innovative drug product


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.